Adaptive Biotechnologies Corporation ADPT
Nov 11, 2026, 2:43 PM EST
- YTD
- +87.65%
- 1 year
- +109.74%
- Market cap
- 4.93B
- Revenue (ttm)
- 298.01M
- Profit margin
- -23.66%
- EPS (ttm)
- -0.45
- Shares out
- 161.88M
- Forward P/E
- -1421.10
- YTD return
- +87.65%
- 1-year return
- +109.74%
- Volume
- 1.70M
- Avg volume
- 2.17M
- Open
- 30.06
- Previous close
- 29.36
- Day's range
- 29.83 – 32.13
- 52-week range
- 12.00 – 32.13
- Beta
- 2.15
- Analysts
- Strong Buy
- Price target
- 32.29 (+5.9%)
- Earnings date
- Feb 4, 2027
5D +4.19 (+15.90%)
Key statistics
- Enterprise value
- 5.02B
- PEG ratio
- 0.00
- Price / sales
- 15.95
- Price / book
- 26.91
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -10.70%
- Free cash flow
- 14.43M
- Total cash
- 298.95M
- Total debt
- 408.97M
- Return on equity
- -36.45%
- Short % of float
- 9.35%
- 50-day average
- 26.52
- 200-day average
- 19.87
Analyst view
Consensus: strong buy
- Target (low)
- 21.00
- Target (mean)
- 32.29
- Target (high)
- 35.00
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate -0.04034.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | -0.06 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.09108 | 0.02 | +0.11 | +121.96% |
| Jul 28, 2026 | Jun 30, 2026 | -0.13361 | -0.25 | -0.12 | -87.11% |
| May 5, 2026 | Mar 31, 2026 | -0.16 | -0.13 | +0.03 | +18.75% |
| Feb 5, 2026 | Dec 31, 2025 | -0.19 | -0.09 | +0.10 | +52.63% |
| Nov 6, 2025 | Sep 30, 2025 | -0.18 | 0.06 | +0.24 | +133.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Guggenheim | main | Buy | Buy |
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 13, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 1, 2026 | Guggenheim | main | Buy | Buy |
| Sep 29, 2026 | Goldman Sachs | init | — | Buy |
| Sep 22, 2026 | BTIG | main | Buy | Buy |
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- adaptivebiotech.com
News
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences 
Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run? 
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34 
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Has Average Target Price of $30.06 
Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript 
Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates 
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates 
Adaptive Biotechnologies Q3 Earnings Call Highlights 
Adaptive Biotechnologies Q3 2026 Earnings Call Transcript 
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
Your note
Sign in to keep a note on ADPT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENZENO SHARON | Officer | Sale | Jun 28, 2026 | 221,278 |
| BOBULSKY SUSAN | Officer | Sale | Oct 5, 2026 | 389,350 |
| LO FRANCIS | Officer | Sale | Sep 30, 2026 | 223,367 |
| NEUPERT PETER M | Director | Sale | Aug 16, 2026 | 130,625 |
| OWEN KATEY EINTERZ | Director | Stock Gift | Aug 30, 2026 | 66,100 |
| PELLINI MICHAEL J | Director | Stock Award(Grant) | Mar 3, 2025 | 69,690 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Viking Global Investors, L.P. | 18.53% | 29,993,708 | 880.62M | Jun 29, 2026 |
| Blackrock Inc. | 9.35% | 15,139,159 | 444.49M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.96% | 6,403,587 | 188.01M | Jun 29, 2026 |
| Wellington Management Group, LLP | 3.65% | 5,911,366 | 173.56M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.38% | 5,476,231 | 160.78M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 2.86% | 4,625,859 | 135.82M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 4,834,309 | 141.94M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.55% | 4,122,023 | 121.02M | Sep 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.13% | 1,825,333 | 53.59M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.08% | 1,742,854 | 51.17M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.04% | 1,687,241 | 49.54M | Aug 30, 2026 |
| ALGER FUNDS-Alger Small Cap Focus Fund | 0.92% | 1,494,214 | 43.87M | Jul 30, 2026 |